...
mgnx-img

MacroGenics Inc, Common Stock

MGNX

NSQ

$3.165

-$0.17

(-5.09%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$209.63M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
561.29K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.08
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.95 L
$21.88 H
$3.165

About MacroGenics Inc, Common Stock

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMGNXSectorS&P500
1-Week Return--3.39%0.2%
1-Month Return-4.84%-1.92%2.72%
3-Month Return-0.74%-10.54%7.31%
6-Month Return-22.14%-4.47%10.44%
1-Year Return-61.52%4.06%27.53%
3-Year Return-79.84%0.94%30.88%
5-Year Return-67.14%36.67%89.21%
10-Year Return-88.58%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue62.02M97.76M75.64M151.94M58.75M[{"date":"2019-12-31","value":40.82,"profit":true},{"date":"2020-12-31","value":64.34,"profit":true},{"date":"2021-12-31","value":49.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.67,"profit":true}]
Cost of Revenue195.31M193.20M2.65M7.38M8.22M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.92,"profit":true},{"date":"2021-12-31","value":1.36,"profit":true},{"date":"2022-12-31","value":3.78,"profit":true},{"date":"2023-12-31","value":4.21,"profit":true}]
Gross Profit(133.28M)97.76M72.99M144.56M50.53M[{"date":"2019-12-31","value":-92.2,"profit":false},{"date":"2020-12-31","value":67.63,"profit":true},{"date":"2021-12-31","value":50.49,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":34.95,"profit":true}]
Gross Margin(214.89%)100.00%96.50%95.14%86.00%[{"date":"2019-12-31","value":-214.89,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.5,"profit":true},{"date":"2022-12-31","value":95.14,"profit":true},{"date":"2023-12-31","value":86,"profit":true}]
Operating Expenses239.21M228.82M275.79M265.98M217.22M[{"date":"2019-12-31","value":86.74,"profit":true},{"date":"2020-12-31","value":82.97,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.44,"profit":true},{"date":"2023-12-31","value":78.76,"profit":true}]
Operating Income(177.19M)(131.06M)(202.79M)(121.42M)(168.24M)[{"date":"2019-12-31","value":-17718500000,"profit":false},{"date":"2020-12-31","value":-13106000000,"profit":false},{"date":"2021-12-31","value":-20279500000,"profit":false},{"date":"2022-12-31","value":-12141800000,"profit":false},{"date":"2023-12-31","value":-16824400000,"profit":false}]
Total Non-Operating Income/Expense--1.36M3.32M167.44M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.81,"profit":true},{"date":"2022-12-31","value":1.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(151.81M)(129.74M)(202.12M)(119.76M)(9.06M)[{"date":"2019-12-31","value":-15181100000,"profit":false},{"date":"2020-12-31","value":-12973900000,"profit":false},{"date":"2021-12-31","value":-20211500000,"profit":false},{"date":"2022-12-31","value":-11975800000,"profit":false},{"date":"2023-12-31","value":-905800000,"profit":false}]
Income Taxes(25.37M)(11.96M)(11.26M)263.00K9.48M[{"date":"2019-12-31","value":-267.74,"profit":false},{"date":"2020-12-31","value":-126.17,"profit":false},{"date":"2021-12-31","value":-118.79,"profit":false},{"date":"2022-12-31","value":2.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes--(190.86M)(120.02M)(18.54M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-19085700000,"profit":false},{"date":"2022-12-31","value":-12002100000,"profit":false},{"date":"2023-12-31","value":-1853510500,"profit":false}]
Income From Continuous Operations(151.81M)(129.74M)(202.12M)(119.76M)(9.06M)[{"date":"2019-12-31","value":-15181100000,"profit":false},{"date":"2020-12-31","value":-12973900000,"profit":false},{"date":"2021-12-31","value":-20211500000,"profit":false},{"date":"2022-12-31","value":-11975800000,"profit":false},{"date":"2023-12-31","value":-905800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(151.81M)(117.78M)(190.86M)(120.02M)(9.06M)[{"date":"2019-12-31","value":-15181100000,"profit":false},{"date":"2020-12-31","value":-11778200000,"profit":false},{"date":"2021-12-31","value":-19085700000,"profit":false},{"date":"2022-12-31","value":-12002100000,"profit":false},{"date":"2023-12-31","value":-905800000,"profit":false}]
EPS (Diluted)(3.56)(2.55)(3.37)(1.94)(1.77)[{"date":"2019-12-31","value":-356,"profit":false},{"date":"2020-12-31","value":-255,"profit":false},{"date":"2021-12-31","value":-337,"profit":false},{"date":"2022-12-31","value":-194,"profit":false},{"date":"2023-12-31","value":-177,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MGNX
Cash Ratio 3.38
Current Ratio 3.75
Quick Ratio 3.69

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MGNX
ROA (LTM) -22.15%
ROE (LTM) -62.17%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MGNX
Debt Ratio Lower is generally better. Negative is bad. 0.55
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.45

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MGNX
Trailing PE NM
Forward PE NM
P/S (TTM) 1.48
P/B 1.69
Price/FCF 4
EV/R 0.26
EV/Ebitda NM
PEG 0.01

FAQs

What is MacroGenics Inc share price today?

MacroGenics Inc (MGNX) share price today is $3.165

Can Indians buy MacroGenics Inc shares?

Yes, Indians can buy shares of MacroGenics Inc (MGNX) on Vested. To buy MacroGenics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MGNX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of MacroGenics Inc be purchased?

Yes, you can purchase fractional shares of MacroGenics Inc (MGNX) via the Vested app. You can start investing in MacroGenics Inc (MGNX) with a minimum investment of $1.

How to invest in MacroGenics Inc shares from India?

You can invest in shares of MacroGenics Inc (MGNX) via Vested in three simple steps:

  • Click on Sign Up or Invest in MGNX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in MacroGenics Inc shares
What is MacroGenics Inc 52-week high and low stock price?

The 52-week high price of MacroGenics Inc (MGNX) is $21.88. The 52-week low price of MacroGenics Inc (MGNX) is $2.95.

What is MacroGenics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of MacroGenics Inc (MGNX) is

What is MacroGenics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of MacroGenics Inc (MGNX) is 1.69

What is MacroGenics Inc dividend yield?

The dividend yield of MacroGenics Inc (MGNX) is 0.00%

What is the Market Cap of MacroGenics Inc?

The market capitalization of MacroGenics Inc (MGNX) is $209.63M

What is MacroGenics Inc’s stock symbol?

The stock symbol (or ticker) of MacroGenics Inc is MGNX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top